JJJeffrey I. Jones

Jeffrey I. Jones

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey I. Jones has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hyperbaric oxygen therapy accelerates wound healing in diabetic mice by decreasing active matrix metalloproteinase‐9

    by Trung T. Nguyen, Jeffrey I. Jones, William R. Wolter, Rocio L. Pérez, Valerie A. Schroeder, Matthew M. Champion, Dusan Hesek, Mijoon Lee, Mark A. Suckow, Shahriar Mobashery, et al.

    Diabetic foot ulcers are characterized by hypoxia. For many patients, hyperbaric oxygen (HBO) therapy is the last recourse for saving the limb from amputation, for which the molecular basis is not understood. We previously identified the active form of matrix metalloproteinase‐9 (MMP‐9) as responsible for diabetic foot ulcer's recalcitrance to healing. Transcription of mmp‐9 to the inactive zymogen is upregulated during hypoxia. Activation of the zymogen is promoted by proteases and reactive oxygen species (ROS). We hypothesized that the dynamics of these two events might lead to a lowering of active MMP‐9 levels in the wounded tissue. We employed the full‐thickness excisional db/db mouse model to study wound healing, and treated the mice to 3.0 atm of molecular oxygen for 90 minutes, 5 days per week for 10 days in an HBO research chamber. Treatment with HBO accelerated diabetic wound healing compared to untreated mice, with more completed and extended reepithelialization. We imaged the wounds for ROS in vivo with a luminol‐based probe and found that HBO treatment actually decreases ROS levels. The levels of superoxide dismutase, catalase, and glutathione peroxidase—enzymes that turn over ROS—increased after HBO treatment, hence the observation of decreased ROS. Since ROS levels are lowered, we explored the effect that this would have on activation of MMP‐9. Quantitative analysis with an affinity resin that binds and pulls down the active MMPs exclusively, coupled with proteomics, revealed that HBO treatment indeed reduces the active MMP‐9 levels. This work for the first time demonstrates that diminution of active MMP‐9 is a contributing factor and a mechanism for enhancement of diabetic wound healing by HBO therapy.


  • Development and application of a high throughput one-pot extraction protocol for quantitative LC-MS/MS analysis of phospholipids in serum and lipoprotein fractions in normolipidemic and dyslipidemic subjects

    by Michael S. Gardner, Zsuzsanna Kuklenyik, Antony Lehtikoski, Kayla A. Carter, Lisa G. McWilliams, Jennifer Kusovschi, Kevin Bierbaum, Jeffrey I. Jones, Jon Rees, Gregory Reis, et al.


  • Open Access

    Targeting MMP-9 in Diabetic Foot Ulcers

    by Jeffrey I. Jones, Trung T. Nguyen, Zhihong Peng, Mayland Chang

    Diabetic foot ulcers (DFUs) are significant complications of diabetes and an unmet medical need. Matrix metalloproteinases (MMPs) play important roles in the pathology of wounds and in the wound healing process. However, because of the challenge in distinguishing active MMPs from the two catalytically inactive forms of MMPs and the clinical failure of broad-spectrum MMP inhibitors in cancer, MMPs have not been a target for treatment of DFUs until recently. This review covers the discovery of active MMP-9 as the biochemical culprit in the recalcitrance of diabetic wounds to healing and targeting this proteinase as a novel approach for the treatment of DFUs. Active MMP-8 and MMP-9 were observed in mouse and human diabetic wounds using a batimastat affinity resin and proteomics. MMP-9 was shown to play a detrimental role in diabetic wound healing, whereas MMP-8 was beneficial. A new class of selective MMP-9 inhibitors shows clinical promise for the treatment of DFUs.


  • Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing

    by Trung T. Nguyen, Derong Ding, William R. Wolter, Rocio L. Pérez, Matthew M. Champion, Kiran V. Mahasenan, Dusan Hesek, Mijoon Lee, Valerie A. Schroeder, Jeffrey I. Jones, et al.

    Diabetic foot ulcers (DFUs) are a significant health problem. A single existing FDA-approved drug for this ailment, becaplermin, is not standard-of-care. We previously demonstrated that upregulation of active matrix metalloproteinase (MMP)-9 is the reason that the diabetic wound in mice is recalcitrant to healing and that MMP-8 participates in wound repair. In the present study, we validate the target MMP-9 by identifying and quantifying active MMP-8 and MMP-9 in human diabetic wounds using an affinity resin that binds exclusively to the active forms of MMPs coupled with proteomics. Furthermore, we synthesize and evaluate enantiomerically pure (R)- and (S)-ND-336, as inhibitors of the detrimental MMP-9, and show that the (R)-enantiomer has superior efficacy in wound healing over becaplermin. Our results reveal that the mechanisms of pathology and repair are similar in diabetic mice and diabetic humans and that (R)-ND-336 holds promise for the treatment of DFUs as a first-in-class therapeutic.


  • Open Access

    Core lipid, surface lipid and apolipoprotein composition analysis of lipoprotein particles as a function of particle size in one workflow integrating asymmetric flow field-flow fractionation and liquid chromatography-tandem mass spectrometry

    by Zsuzsanna Kuklenyik, Jeffery I. Jones, Michael S. Gardner, David M. Schieltz, Bryan A. Parks, Christopher A. Toth, Jon C. Rees, Michael L. Andrews, Kayla Carter, Antony K. Lehtikoski, et al.

    Lipoproteins are complex molecular assemblies that are key participants in the intricate cascade of extracellular lipid metabolism with important consequences in the formation of atherosclerotic lesions and the development of cardiovascular disease. Multiplexed mass spectrometry (MS) techniques have substantially improved the ability to characterize the composition of lipoproteins. However, these advanced MS techniques are limited by traditional pre-analytical fractionation techniques that compromise the structural integrity of lipoprotein particles during separation from serum or plasma. In this work, we applied a highly effective and gentle hydrodynamic size based fractionation technique, asymmetric flow field-flow fractionation (AF4), and integrated it into a comprehensive tandem mass spectrometry based workflow that was used for the measurement of apolipoproteins (apos A-I, A-II, A-IV, B, C-I, C-II, C-III and E), free cholesterol (FC), cholesterol esters (CE), triglycerides (TG), and phospholipids (PL) (phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylethanolamine (PE), phosphatidylinositol (PI) and lysophosphatidylcholine (LPC)). Hydrodynamic size in each of 40 size fractions separated by AF4 was measured by dynamic light scattering. Measuring all major lipids and apolipoproteins in each size fraction and in the whole serum, using total of 0.1 ml, allowed the volumetric calculation of lipoprotein particle numbers and expression of composition in molar analyte per particle number ratios. Measurements in 110 serum samples showed substantive differences between size fractions of HDL and LDL. Lipoprotein composition within size fractions was expressed in molar ratios of analytes (A-I/A-II, C-II/C-I, C-II/C-III. E/C-III, FC/PL, SM/PL, PE/PL, and PI/PL), showing differences in sample categories with combinations of normal and high levels of Total-C and/or Total-TG. The agreement with previous studies indirectly validates the AF4-LC-MS/MS approach and demonstrates the potential of this workflow for characterization of lipoprotein composition in clinical studies using small volumes of archived frozen samples.


  • Open Access

    Simultaneous Quantification of Free Cholesterol, Cholesteryl Esters, and Triglycerides without Ester Hydrolysis by UHPLC Separation and In-Source Collision Induced Dissociation Coupled MS/MS

    by Michael S. Gardner, Lisa G. McWilliams, Jeffrey I. Jones, Zsuzsanna Kuklenyik, James L. Pirkle, John R. Barr

    We demonstrate the application of in-source nitrogen collision-induced dissociation (CID) that eliminates the need for ester hydrolysis before simultaneous analysis of esterified cholesterol (EC) a...


  • Optimization of the linear quantification range of an online trypsin digestion coupled liquid chromatography–tandem mass spectrometry (LC–MS/MS) platform

    by Zsuzsanna Kuklenyik, Jeffrey I. Jones, Christopher A. Toth, Michael S. Gardner, James L. Pirkle, John R. Barr

    Tandem mass spectrometry (MS/MS)-based proteomic workflows with a bottom-up approach require enzymatic digestion of proteins to peptide analytes, usually by trypsin. Online coupling of trypsin digestion of proteins, using an immobilized enzyme reactor (IMER), with liquid chromatography (LC) and MS/MS is becoming a frequently used approach. However, finding IMER digestion conditions that allow quantitative analysis of multiple proteins with wide range of endogenous concentration requires optimization of multiple interactive parameters: digestion buffer flow rate, injection volume, sample dilution, and surfactant type/concentration. In this report, we present a design of experiment approach for the optimization of an integrated IMER-LC-MS/MS platform. With bovine serum albumin as a model protein, the digestion efficacy and digestion rate were monitored based on LC-MS/MS peak area count versus protein concentration regression. The optimal parameters were determined through multivariate surface response modeling and consideration of diffusion controlled immobilized enzyme kinetics. The results may provide guidance to other users for the development of quantitative IMER-LC-MS/MS methods for other proteins.


  • Open Access

    High throughput quantification of apolipoproteins A‐I and B‐100 by isotope dilution MS targeting fast trypsin releasable peptides without reduction and alkylation

    by Bryan A Parks, David M Schieltz, Michael L Andrews, Michael S Gardner, Jon C Rees, Christopher A Toth, Jeffrey I Jones, Lisa G McWilliams, Zsuzsanna Kuklenyik, James L Pirkle, et al.

    Purpose: Apolipoprotein A‐I (ApoA‐I) and apolipoprotein B‐100 (ApoB‐100) are amphipathic proteins that are strong predictors of cardiovascular disease risk. The traceable calibration of apolipoprotein assays is a persistent challenge, especially for ApoB‐100, which cannot be solubilized in purified form.Experimental design: A simultaneous quantitation method for ApoA‐I and ApoB‐100 was developed using tryptic digestion without predigestion reduction and alkylation, followed by LC separation coupled with isotope dilution MS analysis. The accuracy of the method was assured by selecting structurally exposed signature peptides, optimal choice of detergent, protein:enzyme ratio, and incubation time. Peptide calibrators were value assigned by isobaric tagging isotope dilution MS amino acid analysis.Results: The method reproducibility was validated in technical repeats of three serum samples, giving 2–3% intraday CVs (N = 5) and N = 21). The repeated analysis of interlaboratory harmonization standards showed −1% difference for ApoA‐I and −12% for ApoB‐100 relative to the assigned value. The applicability of the method was demonstrated by repeated analysis of 24 patient samples with a wide range of total cholesterol and triglyceride levels.Conclusions and clinical relevance: The method is applicable for simultaneous analysis of ApoA‐I and ApoB‐100 in patient samples, and for characterization of serum pool calibrators for other analytical platforms.


  • On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins

    by Christopher A Toth, Zsuzsanna Kuklenyik, Jeffrey I Jones, Bryan A Parks, Michael S Gardner, David M Schieltz, Jon C Rees, Michael L Andrews, Lisa G McWilliams, James L Pirkle, et al.


  • Open Access

    The effects of apolipoprotein B depletion on HDL subspecies composition and function

    by W. Sean Davidson, Anna Heink, Hannah Sexmith, John T. Melchior, Scott M. Gordon, Zsuzsanna Kuklenyik, Laura Woollett, John R. Barr, Jeffrey I. Jones, Christopher A. Toth, et al.